Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 52

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 52
---
 had a 2024 annualized base salary of $452,494 and an individual bonus target of 40% of his base salary until he was appointed as our Chief Business Officer effective April 21, 2024, at which time his base salary was was increased by 7.2% to $485,000 and his individual bonus target was increased to 45% of his base salary. Dr. Teel’s 2024 bonus amount has been prorated accordingly. Dr. Teel served as our interim Chief Financial Officer, Treasurer and principal financial officer, from February 29, 2024 to June 24, 2024 and his individual bonus target did not change in connection with this interim role.

(3) Mr. Cassidy served as our Chief Financial Officer, Treasurer and principal financial officer until February 29, 2024. Mr. Cassidy did not receive any annual bonus as he was not employed by the company on the payment date.

(4) Dr. Berkowitz was appointed as our Chief Medical Officer effective March 18, 2024. Dr. Berkowitz’s total bonus amount has been prorated accordingly.

(5) Dr. Cacace was appointed Chief Scientific Officer effective June 17, 2024. Dr. Cacace had a 2024 annualized base salary of $431,826 and an individual bonus target of 40% of her base salary until she was named as our Chief Scientific Officer effective June 17, 2024, at which time her base salary was increased by 12.3% to $485,000 and her individual bonus target was increased to 45% of her base salary, retroactive to May 17, 2024. Dr. Cacace’s 2024 bonus amount has been prorated accordingly.

(6) Dr. Taylor served as our Chief Scientific Officer until June 17, 2024 at which time he was appointed as our President of Research and Development. His bonus percentage did not change as a result of his appointment as our President of R&D, but his base salary was decreased from $466,856 to $250,000 to reflect his position and his bonus has been calculated accordingly.

Long-term Incentives

Our equity awards program is designed to:

• reward demonstrated leadership and performance;

• align our executive officers’ interests with those of our stockholders;

• retain our executive officers at least through the term of the awards;

• maintain competitive levels of executive compensation; and

• motivate